197 related articles for article (PubMed ID: 22774922)
1. Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
Rampersaud N; Harkavyi A; Giordano G; Lever R; Whitton J; Whitton P
Br J Pharmacol; 2012 Dec; 167(7):1467-79. PubMed ID: 22774922
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.
Rampersaud N; Harkavyi A; Giordano G; Lever R; Whitton J; Whitton PS
Neuropeptides; 2012 Oct; 46(5):183-93. PubMed ID: 22921965
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Srinivasan J; Schmidt WJ
Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Harkavyi A; Abuirmeileh A; Lever R; Kingsbury AE; Biggs CS; Whitton PS
J Neuroinflammation; 2008 May; 5():19. PubMed ID: 18492290
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
6. Noradrenaline is crucial for the substantia nigra dopaminergic cell maintenance.
Af Bjerkén S; Stenmark Persson R; Barkander A; Karalija N; Pelegrina-Hidalgo N; Gerhardt GA; Virel A; Strömberg I
Neurochem Int; 2019 Dec; 131():104551. PubMed ID: 31542295
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Li Y; Perry T; Kindy MS; Harvey BK; Tweedie D; Holloway HW; Powers K; Shen H; Egan JM; Sambamurti K; Brossi A; Lahiri DK; Mattson MP; Hoffer BJ; Wang Y; Greig NH
Proc Natl Acad Sci U S A; 2009 Jan; 106(4):1285-90. PubMed ID: 19164583
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease.
Aksoy D; Solmaz V; Çavuşoğlu T; Meral A; Ateş U; Erbaş O
Am J Med Sci; 2017 Sep; 354(3):319-324. PubMed ID: 28918840
[TBL] [Abstract][Full Text] [Related]
9. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
11. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
[TBL] [Abstract][Full Text] [Related]
12. Additional noradrenergic depletion aggravates forelimb akinesia and abnormal subthalamic nucleus activity in a rat model of Parkinson's disease.
Wang Y; Chen X; Wang T; Sun YN; Han LN; Li LB; Zhang L; Wu ZH; Huang C; Liu J
Life Sci; 2014 Dec; 119(1-2):18-27. PubMed ID: 25445222
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
14. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
Kumari R; Kumar JB; Luthra PM
Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
[TBL] [Abstract][Full Text] [Related]
15. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
16. Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety.
Vieira JCF; Bassani TB; Santiago RM; de O Guaita G; Zanoveli JM; da Cunha C; Vital MABF
Behav Brain Res; 2019 Oct; 371():111981. PubMed ID: 31141725
[TBL] [Abstract][Full Text] [Related]
17. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Cao LF; Peng XY; Huang Y; Wang B; Zhou FM; Cheng RX; Chen LH; Luo WF; Liu T
Neural Plast; 2016; 2016():6383240. PubMed ID: 27747105
[TBL] [Abstract][Full Text] [Related]
18. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
19. Is nicotine protective against Parkinson's disease? An experimental analysis.
García-Montes JR; Boronat-García A; López-Colomé AM; Bargas J; Guerra-Crespo M; Drucker-Colín R
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):897-906. PubMed ID: 23131151
[TBL] [Abstract][Full Text] [Related]
20. Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats.
Srinivasan J; Schmidt WJ
J Neural Transm (Vienna); 2004 Jan; 111(1):13-26. PubMed ID: 14714212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
